Survival and Prognostic Factors of Metastatic Breast Cancer
Laohavinij, S.; Paul, V.; Maneenil, K.
Journal of the Medical Association of Thailand 100(Suppl 1): S16-S26
2017
ISSN/ISBN: 0125-2208 PMID: 29927171 Document Number: 17536
Prognostic factors for survival of metastatic breast cancer (MBC) patients are important for identifying risks To determine the survival duration and prognostic factors for overall survival in metastatic breast cancer. This retrospective cohort study was conducted by reviewing 232 files of MBC patients treated in the There were 232 patients whose median age was 51.5 years. The 1-year, 3-year and 5-year overall survival rates for MBC patients were 53.2%, 18.7% and 7.3% respectively, and the median overall survival time of all MBC patients was 13.43 months. Multivariate analysis showed that large tumor size T4 (HR = 1.89, 95% CI 1.04-3.44; p = 0.038), ECOG performance status 3-4 (HR = 2.44, 95% CI 1.48-4.00; p<0.001) and treatment with best supportive care only (HR = 5.95, 95% CI 3.56-9.96; p<0.001) were significant prognostic factors for poor overall survival in MBC. Breast cancer subtype analysis showed that luminal-A subtype was associated with a high rate of late recurrence (beyond 2 years) (p = 0.016) and HER-2 enriched subtype was related to a high rate of early relapse (before 2 years (p = 0.001)). The important prognostic factors for overall survival in MBC were tumor size, ECOG PS and type of first-line